Kliniska studier för Amyloidos i Maryland
7 studier för Amyloidos söker deltagare vid platser i Maryland.
Städer i Maryland
Officiell studietext (engelska)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Baltimore
RekryterarObservationsstudie
Ålder 18 till 130 · Alla kön · Uppdaterad 23 sep. 2026 · NCT06465810TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Clinical Trial Site, Baltimore
RekryterarFas 3
Ålder 18 till 85 · Alla kön · Uppdaterad 16 sep. 2026 · NCT07052903TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Clinical Trial Site, Baltimore
RekryterarFas 3
Ålder 18 till 85 · Alla kön · Uppdaterad 15 sep. 2026 · NCT07223203ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Clinical Trial Site, Baltimore
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 8 sep. 2026 · NCT04561518Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- University of Maryland Medical Center, Baltimore
- Johns Hopkins University, Baltimore
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 4 aug. 2026 · NCT06563895Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
- National Institutes of Health Clinical Center, Bethesda
RekryterarFas 1
Ålder 18 till 120 · Alla kön · Uppdaterad 19 maj 2026 · NCT06974877MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Johns Hopkins University, Baltimore
RekryterarFas 3
Ålder 18 till 90 · Alla kön · Uppdaterad 27 mars 2026 · NCT06128629Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.